BLCO Overview

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Wall Street analysts forecast BLCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is18.11 USD with a low forecast of 13.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bausch + Lomb Corp revenue for the last quarter amounts to 1.24B USD, increased 9.41

Bausch + Lomb Corp. EPS for the last quarter amounts to -0.20 USD, decreased -66.67

Bausch + Lomb Corp (BLCO) has 13000 emplpoyees as of July 08 2026.

Today BLCO has the market capitalization of 6.10B USD.